Q3 EPS Estimates for MiNK Therapeutics Lowered by B. Riley

MiNK Therapeutics, Inc. (NASDAQ:INKT) – Analysts at B. Riley cut their Q3 2025 EPS estimates for shares of MiNK Therapeutics in a research report issued on Wednesday, August 20th. B. Riley analyst M. Mamtani now expects that the company will post earnings of ($0.91) per share for the quarter, down from their prior forecast of ($0.71). B. Riley currently has a “Strong-Buy” rating on the stock. The consensus estimate for MiNK Therapeutics’ current full-year earnings is ($2.75) per share. B. Riley also issued estimates for MiNK Therapeutics’ Q4 2025 earnings at ($0.96) EPS, FY2025 earnings at ($3.58) EPS, FY2026 earnings at ($4.17) EPS, FY2027 earnings at ($4.63) EPS, FY2028 earnings at $5.00 EPS and FY2029 earnings at ($5.43) EPS.

MiNK Therapeutics (NASDAQ:INKT) last announced its earnings results on Thursday, August 14th. The company reported ($1.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.51).

INKT has been the topic of several other research reports. William Blair downgraded shares of MiNK Therapeutics from an “outperform” rating to a “market perform” rating in a report on Friday, July 11th. HC Wainwright raised MiNK Therapeutics from a “neutral” rating to a “buy” rating and set a $35.00 price objective on the stock in a report on Friday, August 15th. Finally, Zacks Research downgraded MiNK Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Monday, August 18th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, MiNK Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $37.50.

MiNK Therapeutics Price Performance

Shares of MiNK Therapeutics stock opened at $14.90 on Friday. The firm’s fifty day simple moving average is $14.65 and its 200-day simple moving average is $10.42. The stock has a market capitalization of $67.35 million, a price-to-earnings ratio of -5.17 and a beta of 0.33. MiNK Therapeutics has a 12 month low of $4.56 and a 12 month high of $76.00.

About MiNK Therapeutics

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.